Passage Bio, Inc. (PASG)
PASG Stock Price Chart
Explore Passage Bio, Inc. interactive price chart. Choose custom timeframes to analyze PASG price movements and trends.
PASG Company Profile
Discover essential business fundamentals and corporate details for Passage Bio, Inc. (PASG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Feb 2020
Employees
60.00
Website
https://www.passagebio.comCEO
William Chou
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Financial Timeline
Browse a chronological timeline of Passage Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$2.64.
Earnings released on 12 Aug 2025
EPS came in at -$2.96 surpassing the estimated -$4.00 by +26.00%.
Stock split effective on 14 Jul 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$5.00 falling short of the estimated -$4.80 by -4.17%.
Earnings released on 4 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%.
Earnings released on 13 Nov 2024
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 14 May 2024
EPS came in at -$0.30 surpassing the estimated -$0.37 by +18.92%.
Earnings released on 4 Mar 2024
EPS came in at -$0.30 surpassing the estimated -$0.41 by +26.83%, while revenue for the quarter reached $5.91M .
Earnings released on 13 Nov 2023
EPS came in at -$0.49 falling short of the estimated -$0.47 by -4.26%.
Earnings released on 7 Aug 2023
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%.
Earnings released on 11 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.49 by -28.57%.
Earnings released on 6 Mar 2023
EPS came in at -$0.50 falling short of the estimated -$0.48 by -4.17%.
Earnings released on 10 Nov 2022
EPS came in at -$0.49 surpassing the estimated -$0.75 by +34.67%.
Earnings released on 4 Aug 2022
EPS came in at -$0.73 surpassing the estimated -$0.78 by +6.41%.
Earnings released on 16 May 2022
EPS came in at -$0.79 surpassing the estimated -$0.88 by +10.23%.
Earnings released on 3 Mar 2022
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%.
Earnings released on 4 Nov 2021
EPS came in at -$0.77 surpassing the estimated -$0.80 by +3.75%.
Earnings released on 5 Aug 2021
EPS came in at -$0.90 falling short of the estimated -$0.73 by -23.29%.
Earnings released on 5 May 2021
EPS came in at -$0.76 falling short of the estimated -$0.66 by -15.15%.
Earnings released on 3 Mar 2021
EPS came in at -$0.85 falling short of the estimated -$0.69 by -23.19%.
Earnings released on 10 Nov 2020
EPS came in at -$0.63 surpassing the estimated -$0.73 by +13.70%.
PASG Stock Performance
Access detailed PASG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.